SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

BBIO

BridgeBio Pharma, Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Revenue growth confirms Attruby's commercial trajectory, but the EPS miss may pressure the stock near-term. Key catalysts are the BBP-418 PDUFA in November 2026, encaleret PDUFA in May 2027, and upcoming data at ESC 2026. Monitor Attruby market share gains and the impact of the $1B financing on launch execution.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$84.67
T+0 close · Aug 10, 2026 · via day close
Latest settled
−9.19%
T+60 · $76.89
Vs SPY
−9.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $84.67entry
  2. T+1 · 3mo ago −0.98%α −1.23% · $83.84
  3. T+5 · 3mo ago −2.00%α −1.59% · $82.98
  4. T+20 · 2mo ago −10.15%α −9.09% · $76.08
  5. T+60 · 13d ago −9.19%α −9.06% · $76.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+211% YoY), but GAAP EPS of $(0.78) missed consensus of $(0.64) by 22%. The company is investing heavily in three upcoming launches and closed a $1B preferred equity financing post-quarter, strengthening its balance sheet for pipeline expansion.

Key Financial Metrics

EPS
−$0.78
est −$0.64 · -21.9%
Revenue
$243.7M
+120.3% YoY
Rating
miss

Key Facts

  • Q2 2026 total revenues $243.7M, up 120.5% YoY from $110.6M
  • Attruby net product revenue $222.4M, up 211% YoY from $71.5M
  • GAAP net loss per share $(0.78) vs consensus $(0.64), 21.9% miss
  • Three NDAs under FDA Priority Review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 8, 2027), infigratinib (submitted)
  • $1B preferred equity financing closed July 1, 2026, led by Sixth Street
  • Cash, equivalents, and marketable securities $720.2M as of June 30, 2026
  • Operating expenses surged to $350.8M (+43.3% YoY) as company scales for three launches

Financial Impact

Revenue growth offset by 22% EPS miss and 43% operating expense increase; net loss improved to $152.2M from $181.9M YoY

revenueepsoperating expensescash position

Risk Factors

  • EPS miss of 22% vs consensus raises concerns about expense trajectory
  • R&D and SG&A spending growing faster than revenue, delaying profitability
  • Dependence on Attruby for near-term revenue; pipeline approvals are binary events
  • High debt load with $2.5B in notes and deferred royalty obligations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342182

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026